Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Clin Chest Med. 2016 Mar 4;37(2):241–250. doi: 10.1016/j.ccm.2016.01.007

Figure 3. Mortality of sepsis patients in trials of albumin administration.

Figure 3

Relative risks of death by 28 days with albumin (n=603) versus saline (n=615) for patients with severe sepsis in the SAFE study36, death by 90 days with albumin (n=888) versus crystalloid (n=893) in the ALBIOS study37, and death by 28 days with albumin (n=399) versus saline (n=393) in the EARSS study38 are displayed with accompanying 95% confidence intervals.

Adapted from Wiedermann, C. J. & Joannidis, M. Albumin replacement in severe sepsis or septic shock. N. Engl. J. Med. 371, 83 (2014); with permission.